GS-248

Gesynta Pharma AB · Phase 2 active Small molecule

At a glance

Generic name	GS-248
Sponsor	Gesynta Pharma AB
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis (PHASE2)
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-248 (PHASE1)
A Study in Healthy Subjects to Evaluate Pharmacokinetics and Food Effect After Dosing of GS-248 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GS-248 CI brief — competitive landscape report
GS-248 updates RSS · CI watch RSS
Gesynta Pharma AB portfolio CI